Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation

Mammalian ABC Transporters in Health and Disease

2002 • 1,531 citations

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

2008 • 1,335 citations

Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

1995 • 1,109 citations

Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins

1997 • 934 citations

MDCK (Madin-Darby Canine Kidney) Cells: A Tool for Membrane Permeability Screening

1999 • 895 citations

The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria

2002 • 807 citations

Role of Breast Cancer Resistance Protein in the Bioavailability and Fetal Penetration of Topotecan

2000 • 640 citations

Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA.

1998 • 621 citations

Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.

1999 • 475 citations

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

2004 • 415 citations

The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients

2005 • 348 citations

High-Affinity Interaction of Tyrosine Kinase Inhibitors with the ABCG2 Multidrug Transporter

2004 • 338 citations

Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine

2004 • 278 citations

Distribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated Efflux

2002 • 269 citations

P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan

2007 • 264 citations

An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016): TABLE 1

2008 • 247 citations

The Role of Efflux and Uptake Transporters inN-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and Drug Interactions

2008 • 234 citations

Physiological and pharmacological roles of ABCG2 (BCRP): Recent findings in Abcg2 knockout mice

2008 • 228 citations

Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2

2008 • 217 citations

Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.

1992 • 212 citations

Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression

2008 • 210 citations

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells

2007 • 201 citations

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition inin vitroandin vivopharmacokinetic studies employing Bcrp1−/−/Mdr1a/1b−/− (triple-knockout) and wild-type mice

2008 • 199 citations

Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications

2008 • 191 citations

Gefitinib (“Iressa”, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses Breast Cancer Resistance Protein/ABCG2–Mediated Drug Resistance

2005 • 177 citations

Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells

2005 • 172 citations

Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment

2009 • 169 citations

Interaction of Imatinib Mesilate with Human P-Glycoprotein

2003 • 161 citations

Contribution of the ABC Transporters Bcrp1 and Mdr1a/1b to the Side Population Phenotype in Mammary Gland and Bone Marrow of Mice

2005 • 148 citations

The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic Acid (PF-407288) in Mice

2009 • 142 citations

Blood–brain barrier and chemotherapeutic treatment of brain tumors

2006 • 138 citations

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib

2008 • 137 citations

Influence of breast cancer resistance protein (Abcg2) and p‐glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec^®) across the mouse blood–brain barrier

2007 • 93 citations

Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma

2008 • 40 citations

Liquid chromatography–tandem mass spectrometric assay for sorafenib and sorafenib–glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite

2008 • 38 citations

Renal Cell Cancer Presented with Leptomeningeal Carcinomatosis Effectively Treated with Sorafenib

2007 • 28 citations